This is a summary of the publication about the DESTINY-Gastric01 study, which was published in the New England Journal of Medicine in May 2020. The study included 187 adults in Japan and South Korea with gastric cancer or gastroesophageal junction cancer that had high levels of a protein called HER2 (HER2-positive). All the participants’ cancer had spread to nearby or distant parts of the body and had worsened after receiving at least 2 previous cancer treatments or treatment combinations. The researchers wanted to know whether a drug called trastuzumab deruxtecan (T-DXd) could improve participants’ cancer more than standard chemotherapy drugs.This Plain Language Summary of Publication article from Future Oncology describes a study that included Japanese and South Korean individuals with gastric /gastroesophageal junction cancer that had high levels of a protein called HER2 (HER2-positive). The researchers looked at whether a drug called trastuzumab deruxtecan (T-DXd) could improve participants’ cancer more than standard chemotherapy drugs in participants who had their cancer worsen after receiving at least 2 previous cancer treatments.

Visit the Future Medicine site using the link to read the article.

The original article on which this summary is based on was published in the New England Journal of Medicine and is called ‘Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer’.

Visit the New England Journal of Medicine site using the link to read the article.